Health Care · Biological Products, (No Diagnostic Substances) · OTC · CIK 1001233 · no price history on file
Price series unavailable — No prices available for SGMOQ in [1900-01-01, 2026-07-31]. This symbol may require bring-your-own-key (BYOK) data.
| Days to cover1.3d |
Short interest is FINRA semi-monthly, settlement 2026-07-15.
SGMOQ is not in the screener universe.
No return windows available for SGMOQ.
No risk analytics available for SGMOQ.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 40.4M | $10M | — | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 12.7M | $3M | — | new |
| TWO SIGMA INVESTMENTS, LP | 6.3M | $2M | — | +31.8% |
| Balyasny Asset Management L.P. | 5.3M | $1M | — | new |
| GEODE CAPITAL MANAGEMENT, LLC | 4.6M | $1M | — | +18.2% |
| BlackRock, Inc. | 4.5M | $1M | — | −0.5% |
| RENAISSANCE TECHNOLOGIES LLC | 3.8M | $947,273 | — | −54.5% |
| UBS Group AG | 2.6M | $635,035 | — | +151.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
No reported quarters on file for SGMOQ.
